Le Lézard
Classified in: Health
Subject: PLW

SmartTab Reaches Crucial Milestone with New Patent


DENVER, Jan. 20, 2022 /PRNewswire-PRWeb/ -- The Denver-based startup, SmartTab, continues to revolutionize digital medicine?they successfully obtained a patent for a "wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients."

Smart Pills for Optimized Drug Delivery

This is yet another major stepping stone for the startup. Over the past three years they've quickly made a name for themselves as a leading innovator in wireless drug delivery systems. The company is engaged in the validation of InjectTabtm to replace the needle and syringe for patients with diabetes and autoimmune diseases. Their additional products, TargetTabtm and MultiTabtm have the potential to transform the lives of people suffering from chronic gastrointestinal problems like Crohn's disease.

To maximize medications' effectiveness and minimize side effects, the drug needs to be targeted to the correct location and at the right time. Modern enteric-coated capsules have advanced oral drug delivery by enabling drugs to dissolve after they have bypassed the acidic stomach environment, yet even these capsules can not travel deep into the colon or offer an indication of whether or not the drug was successfully released at the target location.

Patent Details

The patent (U.S. Patent No. 11224383) has SmartTab poised for clinical studies in May. It entails a consumable capsule with a triaxial coil and electronic circuit which interacts with an external device so that the external device can determine the location of the capsule within the gastrointestinal tract. This system of consumable capsule and external tracking and control device delivers a pharmaceutical agent to a predetermined location in the gastrointestinal tract. The capsule electronics can present a signal indicating release of the pharmaceutical agent.

"The new patent issued and soon-to-be-issued patents demonstrate our commitment to advancing a paradigm shift in patient-centered drug delivery."

-Robert Niichel, Chief Executive Officer of SmartTab

Coming Up

SmartTab is presenting at the Annual Arab Health 2022 Conference 24-27 January 2022 at Dubai World Trade Centre?showcasing Colorado's expertise in novel drug delivery systems to the Middle East and international communities. Additionally, they've launched an equity crowdfunding campaign to support their evolution to become the world's leader in ingestible wireless drug delivery.

Media Contact

Sacha Francois Heppell, SmartTab, +1 (720) 220-4152, [email protected]

Twitter

 

SOURCE SmartTab


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: